Brian  Adams net worth and biography

Brian Adams Biography and Net Worth

General Counsel of Relay Therapeutics
Brian Adams brings to Relay more than 15 years of legal and business management experience within the life sciences. Brian joined the company from Keryx Biopharmaceuticals, where he served as senior vice president, general counsel and secretary. Prior to Keryx, he held roles in Algeta ASA, AVEO Oncology and Genzyme Corporation. Before joining Genzyme, Brian practiced at Bingham McCutchen LLP, where he advised private equity sponsors, biotech and other emerging technology companies on a broad range of corporate matters and financing transactions.

Brian holds a B.A. from Harvard University and a J.D. from the Catholic University of America’s Columbus School of Law.

What is Brian Adams' net worth?

The estimated net worth of Brian Adams is at least $319,492.20 as of January 12th, 2023. Mr. Adams owns 51,531 shares of Relay Therapeutics stock worth more than $319,492 as of November 10th. This net worth approximation does not reflect any other investments that Mr. Adams may own. Additionally, Mr. Adams receives an annual salary of $627,720.00 as General Counsel at Relay Therapeutics. Learn More about Brian Adams' net worth.

How old is Brian Adams?

Mr. Adams is currently 50 years old. There are 5 older executives and no younger executives at Relay Therapeutics. The oldest executive at Relay Therapeutics is Dr. David Elliot Shaw Ph.D., Founder, who is 73 years old. Learn More on Brian Adams' age.

What is Brian Adams' salary?

As the General Counsel of Relay Therapeutics, Inc., Mr. Adams earns $627,720.00 per year. There are 3 executives that earn more than Mr. Adams. The highest earning executive at Relay Therapeutics is Dr. Donald A. Bergstrom M.D., Ph.D., President of Research & Development, who commands a salary of $1,370,000.00 per year. Learn More on Brian Adams' salary.

How do I contact Brian Adams?

The corporate mailing address for Mr. Adams and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at [email protected]. Learn More on Brian Adams' contact information.

Has Brian Adams been buying or selling shares of Relay Therapeutics?

Brian Adams has not been actively trading shares of Relay Therapeutics during the last quarter. Most recently, Brian Adams sold 9,994 shares of the business's stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $20.00, for a transaction totalling $199,880.00. Following the completion of the sale, the insider now directly owns 51,531 shares of the company's stock, valued at $1,030,620. Learn More on Brian Adams' trading history.

Who are Relay Therapeutics' active insiders?

Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), and Andy Porter (Insider). Learn More on Relay Therapeutics' active insiders.

Are insiders buying or selling shares of Relay Therapeutics?

In the last twelve months, insiders at the sold shares 18 times. They sold a total of 141,822 shares worth more than $1,108,841.14. The most recent insider tranaction occured on October, 28th when insider Peter Rahmer sold 1,621 shares worth more than $9,823.26. Insiders at Relay Therapeutics own 4.3% of the company. Learn More about insider trades at Relay Therapeutics.

Information on this page was last updated on 10/28/2024.

Brian Adams Insider Trading History at Relay Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2023Sell9,994$20.00$199,880.0051,531View SEC Filing Icon  
9/27/2022Sell294$22.73$6,682.6262,548View SEC Filing Icon  
11/15/2021Sell6,500$35.42$230,230.00View SEC Filing Icon  
9/13/2021Sell6,500$35.02$227,630.0032,077View SEC Filing Icon  
6/7/2021Sell6,500$35.00$227,500.0032,370View SEC Filing Icon  
4/26/2021Sell6,500$35.00$227,500.0032,370View SEC Filing Icon  
1/28/2021Sell5,000$55.05$275,250.0015,000View SEC Filing Icon  
See Full Table

Brian Adams Buying and Selling Activity at Relay Therapeutics

This chart shows Brian Adams's buying and selling at Relay Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Relay Therapeutics Company Overview

Relay Therapeutics logo
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.20
Low: $6.06
High: $6.31

50 Day Range

MA: $6.79
Low: $5.64
High: $9.51

2 Week Range

Now: $6.20
Low: $5.60
High: $12.14

Volume

1,225,076 shs

Average Volume

1,363,811 shs

Market Capitalization

$830.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67